Actively Recruiting
Effect of HFNC on Incidence of Hypoxia During Sedated Gastrointestinal Endoscopy in Critical Patients
Led by Zhejiang University · Updated on 2026-01-20
450
Participants Needed
3
Research Sites
57 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
High flow nasal cannula oxygenation (HFNC) offers high flow and concentration oxygen delivery, providing excellent non-respiratory oxygenation. As a relatively new oxygen delivery method, it has gained widespread use. We have demonstrated that high flow nasal cannula oxygenation reduce the incidence of hypoxia during sedated gastrointestinal endoscopy in patients with American Anesthesiologist Rating (ASA rating) grades 1 to 2 and obesity. We hypothesized that HFNC could mitigate the risk of hypoxia in critical patients during sedated gastrointestinal endoscopy. To confirm this, we selected critical patients with ASA grades 3 to 4 who were scheduled for gastrointestinal endoscopy. We observed and compared the incidence of hypoxia (75%≤SpO2 \< 90% and \< 60S), severe hypoxia (SpO2\<75% for any duration or 75%≤SpO2 \< 90%, ≥60s), subclinical respiratory depression (90%≤SpO2 \< 95%), respiratory-related adverse events, sedation-related adverse events, and complications associated with high flow nasal cannula oxygenation using HFNC or regular nasal cannula during the sedated gastrointestinal endoscopy.
CONDITIONS
Official Title
Effect of HFNC on Incidence of Hypoxia During Sedated Gastrointestinal Endoscopy in Critical Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 80 years
- Undergoing elective gastroenteroscopy or treatment
- American Society of Anesthesiologists (ASA) grade 3 or 4
- Body mass index (BMI) between 18 and 28 kg/m2
- Gastroenteroscopy expected to last no more than 60 minutes
- Able to understand and voluntarily agree to participate with informed consent
You will not qualify if you...
- Nasal congestion, nasal bleeding, recent nasal trauma, recent nasal surgery, increased intracranial pressure, or skull fracture preventing high-flow nasal oxygen
- Acute respiratory infections or asthma attacks
- Diagnosis of chronic obstructive pulmonary disease (COPD)
- Known difficult airway
- Acute upper gastrointestinal bleeding with shock
- Gastrointestinal obstruction with retained stomach contents
- Allergy to sedatives such as propofol
- Cognitive dysfunction or inability to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Shenzhen Hospital of Southern Medical University
Shenzhen, Guangdong, China, 518000
Actively Recruiting
2
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
Shenzhen, Guangdong, China, 518116
Actively Recruiting
3
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310000
Actively Recruiting
Research Team
D
Diansan SU, Cheif of Anesthesiology Department, PhD
CONTACT
S
Shuying Fu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here